Hata T, Yamada T, Goto Y, Amano A, et al. Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients. Lung Cancer 2025;200:108104.
PMID: 39889466